Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Nkarta, Inc., a a clinical-stage biopharmaceutical company, develops and commercializes cell therapies for cancer treatment. The company's approach for cellular immunotherapy involves chimeric antigen receptors on the surface of a natural killer (NK) cell that enable the cell to recognize specific proteins or antigens that are present on the surface of tumor cells. Its two co-lead product candidates are NKX101, which is in Phase I clinical trials for the treatment of relapsed/refractory acute myeloid leukemia or higher risk myelodysplastic syndromes; and NKX019, a pre-clinical product, which is based on the ability to treat various B cell malignancies by targeting the CD19 antigen found on these types of cancerous cells. The company has a research collaboration agreement with CRISPR Therapeutics AG. Nkarta, Inc. was incorporated in 2015 and is based in South San Francisco, California.

Nkarta, Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

SOUTH SAN FRANCISCO, CALIF., DEC. 02, 2025 (GLOBE NEWSWIRE) -- NKARTA, INC. (NASDAQ: NKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING ENGINEERED NATURAL KILLER (NK) CELL THERAPIES TO TREAT AUTOIMMUNE DISEASES, TODAY ANNOUNCED ITS PARTICIPATION IN THE EVERCORE 8TH ANNUAL HEALTHCARE CONFERENCE ON THURSDAY IN MIAMI.

NKARTA TO PARTICIPATE IN EVERCORE HEALTHCARE CONFERENCE

ENROLLMENT NOW UNDERWAY IN SECOND DOSE-ESCALATION COHORT DEEP B-CELL DEPLETION OBSERVED IN ALL PATIENTS TREATED TO DATE WHO RECEIVED NKX019 WITH LYMPHODEPLETION USING FLUDARABINE AND CYCLOPHOSPHAMIDE VERSUS PARTIAL B-CELL DEPLETION IN PATIENTS RECEIVING ONLY CYCLOPHOSPHAMIDE ENROLLMENT STREAMLINED ACROSS NTRUST-1 AND NTRUST-2 UNDER A COMBINED INDEPENDENT DATA SAFETY MONITORING BOARD (IDSMB) TO GUIDE DOSE ESCALATION INITIAL DATA FOR NKX019 IN MULTIPLE AUTOIMMUNE INDICATIONS EXPECTED TO BE PRESENTED AT A MEDICAL CONFERENCE IN 2026 CASH BALANCE OF $316.5 MILLION ON SEPTEMBER 30, 2025, INCLUDING CASH, CASH EQUIVALENTS, AND INVESTMENTS, EXPECTED TO FUND OPERATIONS INTO 2029 SOUTH SAN FRANCISCO, CALIF., NOV. 10, 2025 (GLOBE NEWSWIRE) -- NKARTA, INC. (NASDAQ: NKTX), A CLINICAL-STAGE BIOTECHNOLOGY COMPANY DEVELOPING ENGINEERED NATURAL KILLER (NK) CELL THERAPIES TO TREAT AUTOIMMUNE DISEASES, TODAY REPORTED FINANCIAL RESULTS FOR THE THIRD QUARTER ENDED SEPTEMBER 30, 2025.

NKARTA REPORTS THIRD QUARTER 2025 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS

SOUTH SAN FRANCISCO, CALIF., OCT. 30, 2025 (GLOBE NEWSWIRE) -- NKARTA, INC. (NASDAQ: NKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING ENGINEERED NATURAL KILLER (NK) CELL THERAPIES, TODAY ANNOUNCED ITS PARTICIPATION IN THE FOLLOWING INVESTOR CONFERENCES NEXT MONTH:

NKARTA TO PARTICIPATE IN NOVEMBER INVESTOR CONFERENCES

SOUTH SAN FRANCISCO, CALIF., OCT. 22, 2025 (GLOBE NEWSWIRE) -- NKARTA, INC. (NASDAQ: NKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING ENGINEERED NATURAL KILLER (NK) CELL THERAPIES TO TREAT AUTOIMMUNE DISEASE, TODAY ANNOUNCED IT WILL BE PRESENTING A POSTER THIS SUNDAY IN CHICAGO AT THE AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CONVERGENCE 2025 MEETING.

NKARTA ANNOUNCES POSTER PRESENTATION AT UPCOMING AMERICAN COLLEGE OF RHEUMATOLOGY (ACR) CONVERGENCE MEETING

SOUTH SAN FRANCISCO, CALIF., SEPT. 02, 2025 (GLOBE NEWSWIRE) -- NKARTA, INC. (NASDAQ: NKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING ENGINEERED NATURAL KILLER (NK) CELL THERAPIES, TODAY ANNOUNCED ITS PARTICIPATION IN THE FOLLOWING INVESTOR CONFERENCE:

NKARTA TO PARTICIPATE IN A SEPTEMBER INVESTOR CONFERENCE

SOUTH SAN FRANCISCO, CALIF., AUG. 12, 2025 (GLOBE NEWSWIRE) -- NKARTA, INC. (NASDAQ: NKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING ENGINEERED NATURAL KILLER (NK) CELL THERAPIES, TODAY REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER AND YEAR ENDED JUNE 30, 2025. WE REMAIN FOCUSED ON THE EXECUTION OF OUR CLINICAL TRIALS AND CONTINUE TO BELIEVE IN THE DIFFERENTIATED POTENTIAL OF NK CELL THERAPY TO ADDRESS UNMET NEEDS IN THE TREATMENT OF AUTOIMMUNE DISEASES, SAID PAUL J. HASTINGS, CEO OF NKARTA. WELCOMING DR. ROSE AND OTHER KEY NEW MEMBERS OF OUR CLINICAL TEAM WITH RHEUMATOLOGY EXPERIENCE HAS PROVIDED US WITH WORLD-CLASS MEDICAL EXPERTISE TO INFORM OUR ONGOING ENROLLMENT OF PATIENTS ACROSS OUR CLINICAL STUDIES AND INVESTIGATOR-SPONSORED TRIALS. DR. ROSE'S TRACK RECORD AS A SEASONED RHEUMATOLOGIST, IMMUNOLOGIST AND ACCOMPLISHED DRUG DEVELOPER IN THE AUTOIMMUNE SPACE WILL BE INVALUABLE AS WE CONTINUE TO ADVANCE OUR NKX019 CLINICAL TRIAL PROGRAMS.

NKARTA REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS

SOUTH SAN FRANCISCO, CALIF., JULY 23, 2025 (GLOBE NEWSWIRE) -- NKARTA, INC. (NASDAQ: NKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING ENGINEERED NATURAL KILLER (NK) CELL THERAPIES, TODAY ANNOUNCED ITS PARTICIPATION IN THE H.C. WAINWRIGHT HCW@HOME SERIES.

NKARTA TO PARTICIPATE IN THE H.C. WAINWRIGHT HCW@HOME SERIES

SOUTH SAN FRANCISCO, CALIF., JUNE 06, 2025 (GLOBE NEWSWIRE) -- NKARTA, INC. (NASDAQ: NKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING ENGINEERED NATURAL KILLER (NK) CELL THERAPIES TO TREAT AUTOIMMUNE DISEASE, TODAY ANNOUNCED THE APPOINTMENT OF SHAWN ROSE, M.D. PH.D., AS ITS NEXT CHIEF MEDICAL OFFICER (CMO) AND HEAD OF RESEARCH AND DEVELOPMENT (R&D) STARTING ON JUNE 23, 2025. HE REPLACES DAVID R. SHOOK, M.D., WHO WILL BE STEPPING DOWN FROM THE ROLE TO PURSUE OTHER OPPORTUNITIES IN THE ONCOLOGY SPACE.

NKARTA APPOINTS SHAWN ROSE CHIEF MEDICAL OFFICER & HEAD OF R&D AS COMPANY RESETS SENIOR LEADERSHIP ROLE FOR AUTOIMMUNE FOCUS

ENROLLMENT OPEN IN INVESTIGATOR-SPONSORED TRIAL (IST) OF NKX019 IN MYASTHENIA GRAVIS; NTRUST-1, NTRUST-2, AND IST OF NKX019 IN SYSTEMIC LUPUS ERYTHEMATOSUS REMAIN OPEN TO ENROLLMENT NTRUST-1 EXPANDED TO INCLUDE PRIMARY MEMBRANOUS NEPHROPATHY COHORT LYMPHODEPLETION REGIMEN MODIFIED ACROSS PLATFORM TO INCLUDE FLUDARABINE AND CYCLOPHOSPHAMIDE WITH CYCLOPHOSPHAMIDE ALONE REMAINING AVAILABLE FOR ELIGIBLE PATIENTS INITIAL DATA FOR NKX019 IN MULTIPLE AUTOIMMUNE INDICATIONS EXPECTED IN SECOND HALF OF 2025 CASH BALANCE OF $351.9 MILLION ON MARCH 31, 2025, INCLUDING CASH, CASH EQUIVALENTS AND INVESTMENTS, EXPECTED TO FUND OPERATIONS INTO 2029 SOUTH SAN FRANCISCO, CALIF., MAY 14, 2025 (GLOBE NEWSWIRE) -- NKARTA, INC. (NASDAQ: NKTX), A CLINICAL-STAGE BIOPHARMACEUTICAL COMPANY DEVELOPING ENGINEERED NATURAL KILLER (NK) CELL THERAPIES, TODAY REPORTED FINANCIAL RESULTS FOR THE FIRST QUARTER AND YEAR ENDED MARCH 31, 2025.

NKARTA REPORTS FIRST QUARTER 2025 FINANCIAL RESULTS AND CORPORATE HIGHLIGHTS

SOUTH SAN FRANCISCO, CALIF., APRIL 01, 2025 (GLOBE NEWSWIRE) -- NKARTA, INC. (NASDAQ: NKTX), A BIOPHARMACEUTICAL COMPANY DEVELOPING ENGINEERED NATURAL KILLER (NK) CELL THERAPIES, TODAY ANNOUNCED ITS PARTICIPATION IN THE FOLLOWING INVESTOR CONFERENCE:

Nkarta, Inc.

NKTX

Price

Financial Reports

No items found.

Press Releases

Nkarta, Inc.

NKTX.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

NKTX